Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Texas Biotech (TXB) -- Ignore unavailable to you. Want to Upgrade?

To: debra vogt who wrote (767)	2/22/2000 8:54:00 AM
From: opalapril	Respond to of 834

Approvable. Texas Biotech anticlotting drug approvable HOUSTON, Feb 22 (Reuters) - Texas Biotechnology Corp. <TXB.A> said Tuesday that it has received an approvable letter from the U.S. Food & Drug Administration for its anticlotting drug Novastan, and that it expects to satisfy requirements for final approval within about 60 days. Novastan has been developed as an anticoagulant therapy for patients who can no longer receive heparin, a widely used anti-clotting drug. It is indicated as an anticoagulant for prevention or treatment of thrombosis, or clotting, in patients with heparin-induced thrombocytopenia. Thrombocytopenia is a life-threatening condition in which there is an abnormally small number of platelets in the blood. Heparin-induced thrombocytopenia is an adverse reaction to heparin. Under an August 1997, agreement with SmithKline Beecham Plc <SB.L>, SmithKline has the rights to market and co-develop Novastan in the United States and Canada. Texas Biotechnology said that it has begun commercial-scale manufacturing of Novastan. 08:14 02-22-00